Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wealth Enhancement Advisory Services LLC lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAKFree Report) by 0.7% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 130,904 shares of the company’s stock after buying an additional 857 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Takeda Pharmaceutical were worth $1,818,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Capital Research Global Investors lifted its stake in shares of Takeda Pharmaceutical by 3.6% during the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after buying an additional 503,446 shares in the last quarter. Brandes Investment Partners LP increased its holdings in Takeda Pharmaceutical by 47.1% in the 4th quarter. Brandes Investment Partners LP now owns 2,651,265 shares of the company’s stock valued at $37,834,000 after acquiring an additional 849,229 shares during the last quarter. Managed Asset Portfolios LLC increased its holdings in Takeda Pharmaceutical by 1.2% in the 4th quarter. Managed Asset Portfolios LLC now owns 1,758,081 shares of the company’s stock valued at $25,088,000 after acquiring an additional 21,665 shares during the last quarter. Van ECK Associates Corp increased its holdings in Takeda Pharmaceutical by 3.6% in the 4th quarter. Van ECK Associates Corp now owns 1,323,916 shares of the company’s stock valued at $18,892,000 after acquiring an additional 45,616 shares during the last quarter. Finally, OLD Mission Capital LLC increased its holdings in Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after acquiring an additional 973,935 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $13.22 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.58 and a current ratio of 1.11. The company has a market cap of $41.84 billion, a P/E ratio of 24.04, a P/E/G ratio of 0.37 and a beta of 0.54. The firm’s fifty day moving average is $13.15 and its two-hundred day moving average is $13.86. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $16.39.

Takeda Pharmaceutical Profile

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Further Reading

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.